Neoadjuvant Therapy in Non-Small Cell Lung Cancer

Yifan Zheng; Michael T Jaklitsch; Raphael Bueno

doi:10.1016/j.soc.2016.02.010

Neoadjuvant Therapy in Non-Small Cell Lung Cancer

Surg Oncol Clin N Am. 2016 Jul;25(3):567-84. doi: 10.1016/j.soc.2016.02.010.

Authors

Yifan Zheng¹, Michael T Jaklitsch¹, Raphael Bueno²

Affiliations

¹ Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
² Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 27261916
DOI: 10.1016/j.soc.2016.02.010

Abstract

Locally advanced (stage IIIA) non-small cell lung cancer (NSCLC) is confined to the chest, but requires more than surgery to maximize cure. Therapy given preoperatively is termed neoadjuvant, whereas postoperative therapy is termed adjuvant. Trimodality therapy (chemotherapy, radiation, and surgery) has become the standard treatment regimen for resectable, locally advanced NSCLC. During the past 2 decades, several prospective, randomized, and nonrandomized studies have explored various regimens for preoperative treatment of NSCLC. The evaluation of potential candidates with NSCLC for neoadjuvant therapy as well as the currently available therapeutic regimens are reviewed.

Keywords: Chemotherapy; Lung cancer; N2 nodal disease; Neoadjuvant concurrent therapy; Preoperative therapy; Radiation therapy; Stage IIIA non–small cell lung cancer (NSCLC); Stage IIIA(N2).

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / therapy*
Chemotherapy, Adjuvant*
Combined Modality Therapy / methods*
Humans
Lung Neoplasms / therapy*
Neoadjuvant Therapy*
Neoplasm Staging
Radiotherapy*
Randomized Controlled Trials as Topic
Treatment Outcome